ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + Alendronate
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Post-Menopausal Osteoporosis
Conditions
Post-Menopausal Osteoporosis
Trial Timeline
Jul 1, 2007 โ Apr 1, 2010
NCT ID
NCT00503113About ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + Alendronate
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + Alendronate is a approved stage product being developed by Roche for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00503113. Target conditions include Post-Menopausal Osteoporosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00503113 | Approved | Completed |
Competing Products
19 competing products in Post-Menopausal Osteoporosis